About Us

Founded in Canada in 2015, Virogin aims to unleash synergy between oncolytic virotherapy and mRNA vaccines in the battle against cancer. Our vision is to be a global, best-in-class immuno-oncology company that creates impactful drugs for patients with the highest medical needs.

Highlights of Virogin

• Savvy pre-clinical and clinical teams with >25 years of successful experience leading to numerous regulatory milestones in the US and China
• Immunomodulatory payloads armed oncolytic tumor vaccines (OV) to overcome the immunosuppressive tumor microenvironment
• Demonstrated clinical safety and efficacy of OV monotherapy in various therapeutic areas
• Durable anti-tumor efficacy elicited by combining OV with mRNA vaccines overcoming hurdles presented in tumor vaccines
• Established capability of process development and manufacturing with extensive experience and know-hows in virus and mRNA-based therapeutics production

September 2022
Strategic Collaboration with MD Anderson Cancer Center
February 2022
Virogin USA established
January 2022
VG161 US IND approval; VG201 US IND approval
December 2021
D2 Financing
September 2021
Initiated construction of R&D and Manufacturing Center, Shanghai
May 2021
D1 Financing
September 2020
C Financing
May 2019
CNBG-Virogin Joint Venture established
November 2018
B2 Financing
May 2018
Virogin Biotech Australia established
April 2018
Shanghai Virogin Biotech established
February 2018
B1 Financing
January 2017
A2 Financing
February 2016
A1 Financing
August 2015
Seed Financing; Shenzhen Virogin Biotech established
April 2015
Virogin Biotech Hong Kong established; Virogin Biotech Canada established

Our Leadership Team

Chris Huang, DBA, CFA

Chief Executive Officer, Co-Founder

William Jia, PhD.

Chief Scientific Officer, Co-Founder

Ronghua Zhao, MD, PhD.

Chief Medical Officer

Shah Rahimian, MD

Chief Medical Officer, North America

Dr. Susie Tan, MD, PhD.

Chief Medical Officer, Asia-Pacific

Huanyu Zhao, MBA, PhD.

Senior Vice President

Scientific Advisory Board

Robert (Bob) L. Martuza

Massachusetts General Hospital

George R. Blumenschein

University of Texas MD Anderson Cancer Center

Katy Rezvani

University of Texas MD Anderson Cancer Center

Howard L. Kaufman

Ankyra Therapeutics

Li Jin

President of Fudan University